| I-05 Florence Loingeville Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties Wednesday 10:30-12:00 |
| I-22 Sandrine Micallef Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development Wednesday 10:30-12:00 |
| I-32 Kayode Ogungbenro Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A Wednesday 10:30-12:00 |
| I-49 Philippe Pierrillas Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology Wednesday 10:30-12:00 |
| I-69 Franziska Schädeli Stark Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population Wednesday 10:30-12:00 |
| II-52 Janak Wedagedera Statistical Power Analysis to Detect Drug-Drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modelling and the Simcyp R Package Wednesday 15:10-16:30 |
| III-04 Ruben Faelens Clinical trial optimization of efficacy studies in slowly progressive diseases Thursday 09:50-11:20 |
| III-25 Anubha Gupta Power calculation methods to detect covariates effect when combining observed and simulated data. Thursday 09:50-11:20 |
| III-39 Julie Janssen Clinical trial simulations to optimize dose finding studies in paediatric oncology Thursday 09:50-11:20 |
| IV-39 Chao Chen A clinical trial simulation study to investigate and compare efficacy and toxicity findings in parallel and titration designs Thursday 14:45-16:15 |
